Sulphasalazine has been established to be an effective drug for second line treatment of early mild to moderate rheumatoid arthritis. Its application for juvenile chronic arthritis (JCA) is limited so far and controversial results for the efficacy of this therapy have been published. We studied the efficacy and tolerance of the sulphasalazine treatment in 32 patients with JCA (10 with polyarthritis, 21 with pauciarthritis and 1 with systemic form). Our results revealed significant response of the treatment at the end of the 6th month in 24/31 patients (77%). In one patient the treatment was discontinued because of transitory neutropenia at the end of the 1st month. No significant difference was observed between the efficacy of the treatment in the polyarticular and pauciarticular disease, as well as newly-diagnosed cases and those with longstanding disease. From the group of 17 children treated up to the end of the 1st year 88% achieved complete remission. No serious toxic effects were observed, with the exception of two cases with transitory low-grade neutropenia. According to our results sulphasalazine is an effective and well tolerated drug for second line treatment of JCA-patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The growing range of complications of diabetes mellitus.
Trends Endocrinol Metab
January 2025
School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
With the rising prevalence of type 2 diabetes mellitus (T2DM) and obesity, several previously under-recognised complications associated with T2DM are becoming more evident. The most common of these emerging complications are metabolic dysfunction-associated steatotic liver disease (MASLD), cancer, dementia, sarcopenia, and frailty, as well as other conditions involving the lung, heart, and intestinal tract. Likely causative factors are chronic inflammation and insulin resistance, whereas blood glucose levels appear to play a lesser role.
View Article and Find Full Text PDFClinical implications of human Parvovirus B19 infection on autoimmunity and autoimmune diseases.
Int Immunopharmacol
January 2025
Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan; Department of Clinical Laboratory, Chung Shan Medical University Hospital, Taichung 402, Taiwan; Immunology Research Center, Chung Shan Medical University, Taichung 402, Taiwan. Electronic address:
Parvovirus B19 (B19V) is a human pathogen from the Parvoviridae family that primarily targets and replicates in erythroid progenitor cells (EPCs). While its symptoms are typically self-limiting in healthy individuals, B19V can cause or exacerbate autoimmune diseases in vulnerable patients. This review integrates the involvement of B19V in the development and worsening of several autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), hematological disorders (thalassemia, anemia, and thrombocytopenia), vasculitis, antiphospholipid syndrome (APS), dermatological disease (systemic sclerosis, psoriasis), autoimmune thyroid disease, myocarditis, and myasthenia gravis, and autoinflammatory disease of adult-onset Still's disease (AOSD).
View Article and Find Full Text PDFThe dual endothelin A and angiotensin II type 1 receptor antagonist sparsentan (FILSPARI®) exhibits a safe nonclinical male fertility toxicity profile.
Regul Toxicol Pharmacol
December 2024
Division of Nephrology, University of Utah Health, Salt Lake City, UT, USA.
Marketed endothelin receptor antagonists (ERAs) have been associated with testicular tubular atrophy and decreases in male animal fertility in chronic toxicity studies in rats and dogs. Consistent with these findings, reduced sperm count has been observed in the clinical setting and is considered a potential class risk with chronic administration of ERAs. In contrast, no such effects on male animal fertility are noted with angiotensin II type 1 receptor blocker (ARB) treatment.
View Article and Find Full Text PDFAssessing the Clinical Utility of Antinuclear Antibody Titer Dilutions, Antinuclear Antibody Staining Patterns, and Other Common Laboratory Tests in Juvenile Idiopathic Arthritis.
Cureus
December 2024
Family Medicine, MJ Medical Group, Chicago, USA.
Chronic musculoskeletal pain in pediatric patients can be challenging to diagnose, particularly in the absence of overt signs of autoimmune disease, as these episodes can manifest episodically. We present a case of a 14-year-old female patient with a two-year history of episodic "bone pain," morning stiffness, and infrequent fever and fatigue. Laboratory testing revealed an antinuclear antibody (ANA) titer of 1:1280 with a nuclear homogeneous pattern and a mildly elevated erythrocyte sedimentation rate (ESR).
View Article and Find Full Text PDFResponse of the photosynthetic physiology of Ulva lactuca to Cu toxicity under ocean acidification.
Aquat Toxicol
December 2024
Jiangsu Key Laboratory of Marine Bioresources and Environment, Jiangsu Ocean University, Lianyungang 222005, PR China; Co-Innovation Center of Jiangsu Marine Bio-industry Technology, Lianyungang 222005, PR China.
Ocean acidification can significantly affect the physiological performance of macroalgae. While copper (Cu) is an essential element for macroalgae and has been extensively studied, the interactive effects of ocean acidification and Cu on these organisms remain less understood. In this study, we measured the photosynthetic characteristics of Ulva lactuca exposed to varying Cu concentrations at two CO levels (415 ppmv, low concentration; 1000 ppmv, high concentration).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!